|
| 36791474 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 34824288 | Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. | NPJ Breast Cancer | 2021 |
| 33828257 | Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. | British Journal of Cancer | 2021 |
| 34257082 | Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations. | Cancer Res | 2021 |
| 34250397 | Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. | JCO Precis Oncol | 2021 |
| 33863913 | Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. | NPJ Breast Cancer | 2021 |
| 32888433 | FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. | Cancer Cell | 2020 |
| 32029534 | Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma Cancers. | Cancer Discov | 2020 |
| 32312891 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 31932695 | ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. | Nat Genet | 2020 |
| 31924513 | Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. | Clinical Breast Cancer | 2020 |
| 32463152 | A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. | Oncologist | 2020 |
| 32085669 | Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. | Int J Mol Sci | 2020 |
| 31915197 | Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. | Cancer Discov | 2020 |
| 31806627 | Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer. | Cancer Discov | 2020 |
| 32503877 | Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. | Sci Immunol | 2020 |
| 33106634 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis. | Nat Genet | 2020 |
| 30770493 | Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. | Clinical Cancer Research | 2019 |
| 31699932 | Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. | Science | 2019 |
| 31723286 | A view on drug resistance in cancer. | Nature | 2019 |
| 32914022 | Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. | JCO Precis Oncol | 2019 |
| 30158597 | Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. | Mod Pathol | 2019 |
| 29878225 | Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. | J Natl Cancer Inst | 2019 |
| 30543347 | Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. | JAMA Oncol | 2019 |
| 30387498 | A novel vascular tumour characterized by coexisting HRAS and GNAQ activating mutations. | British Journal of Dermatology | 2019 |
| 30576871 | Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. | J Mol Diagn | 2019 |
| 30335191 | Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. | Cancer | 2019 |
| 30422229 | Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology-Head & Neck Surgery. | JAMA Otolaryngology - Head and Neck Surgery | 2019 |
| 30422162 | Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology. | JAMA Oncology | 2019 |
| 30376427 | Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. | J Clin Oncol | 2019 |
| 30643254 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. | Nat Genet | 2019 |
| 30624662 | Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. | Annals of Oncology | 2019 |
| 30624616 | Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. | Ann Oncol | 2019 |
| 30624609 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | Annals of Oncology | 2019 |
| 30624607 | Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. | Annals of Oncology | 2019 |
| 30624604 | Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. | Annals of Oncology | 2019 |
| 30624599 | Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. | Annals of Oncology | 2019 |
| 30624595 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. | Ann Oncol | 2019 |
| 30624555 | Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. | Ann Oncol | 2019 |
| 31284184 | The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. | Eur J Cancer | 2019 |
| 30976844 | Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. | Cancer Chemother Pharmacol | 2019 |
| 30755741 | Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. | Nature | 2019 |
| 30814109 | Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. | Clin Cancer Res | 2019 |
| 30694565 | MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. | Int J Cancer | 2019 |
| 30862692 | Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. | Clinical Cancer Research | 2019 |
| 31013327 | Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. | PLoS One | 2019 |
| 30679318 | Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. | Oncologist | 2019 |
| 31402321 | Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Oncol | 2019 |
| 31377477 | Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. | European Journal of Cancer | 2019 |
| 30943409 | PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. | Cell Rep | 2019 |